PriceTargets.com logo

Propanc Biopharma - PPCB Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.82 As of 05/29/2026 05:00 PM ET
▲ +0.12 (7.06%)

This chart shows the closing price for PPCB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Propanc Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PPCB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PPCB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Propanc Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.82.

This chart shows the closing price for PPCB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Propanc Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/31/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/1/2026Weiss RatingsUpgradeSell (E) ➝ Sell (E+)
1/14/2026Weiss RatingsInitiated CoverageSell (E-)
(Data available from 5/31/2021 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/31/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/31/2026

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Propanc Biopharma logo
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Read More

Today's Range

Now: $1.82
Low: $1.71
High: $1.94

50 Day Range

MA: $2.47
Low: $1.62
High: $3.15

52 Week Range

Now: $1.82
Low: $1.56
High: $270.25

Volume

68,369 shs

Average Volume

63,163 shs

Market Capitalization

$4.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Propanc Biopharma?

The following Wall Street sell-side analysts have issued reports on Propanc Biopharma in the last twelve months: Weiss Ratings.
View the latest analyst ratings for PPCB.

What is the current price target for Propanc Biopharma?

0 Wall Street analysts have set twelve-month price targets for Propanc Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Propanc Biopharma in the next year.
View the latest price targets for PPCB.

What is the current consensus analyst rating for Propanc Biopharma?

Propanc Biopharma currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe PPCB will underperform the market and that investors should sell shares of Propanc Biopharma.
View the latest ratings for PPCB.

What other companies compete with Propanc Biopharma?

Other companies that are similar to Propanc Biopharma include Natural Alternatives International, GT Biopharma, Applied Therapeutics, Cocrystal Pharma and Traws Pharma. Learn More about companies similar to Propanc Biopharma.

How do I contact Propanc Biopharma's investor relations team?

Propanc Biopharma's physical mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company's listed phone number is (139) 882-0780 and its investor relations email address is [email protected]. The official website for Propanc Biopharma is www.propanc.com. Learn More about contacing Propanc Biopharma investor relations.